<!DOCTYPE html>
<html lang="en" style="--theme-color: #262626; --link-color: #262626;">
<head>
  <meta charset="UTF-8">
  <title>医学翻译学习-alirocumab与急性冠脉综合征后的心血管结局 - 王楠鑫|Curtis_一个医学译者的前后左右</title>

  <link rel="icon" href="">
<!-- <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet"> -->
<link rel="alternate" type="application/atom+xml" title="王楠鑫|Curtis_一个医学译者的前后左右 - Atom Feed" href="https://airmedtrans.com/atom.xml">

  

  
  <!-- Global site tag (gtag.js) - Google Analytics -->
  <!-- <script async src="https://www.googletagmanager.com/gtag/js?id=G-NFCRR8Q57W"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
  </script> -->
  <script async src='https://www.google-analytics.com/analytics.js'></script>



  <script>
    window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
    ga('create', 'UA-182385326-1');
    ga('set', 'dimension1', 'site/cbS9tMKNT');
    ga('set', 'dimension2', 'post/AAdVfSCx7');
    ga('send', 'pageview');
    // gtag('set', {
    //   'custom_map': {
    //     'dimension1': 'siteId',
    //     'dimension2': 'postId',
    //   }
    // })

    // gtag('config', 'G-NFCRR8Q57W', {
    //   'siteId': 'site/cbS9tMKNT',
    //   'postId': 'post/AAdVfSCx7',
    // });
  </script>





  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="关于“alirocumab与急性冠脉综合征后的心血管结局”的翻译学习，学习内容记录于此。
旧文重发，时间为2019-03-15

背景
BACKGROUND

急性冠脉综合征患者发生复发性缺血性心血管事件的风险较高。
Patients wh...">

  <meta property="og:title" content="医学翻译学习-alirocumab与急性冠脉综合征后的心血管结局 - 王楠鑫|Curtis_一个医学译者的前后左右">
  <meta property="og:description" content="关于“alirocumab与急性冠脉综合征后的心血管结局”的翻译学习，学习内容记录于此。
旧文重发，时间为2019-03-15

背景
BACKGROUND

急性冠脉综合征患者发生复发性缺血性心血管事件的风险较高。
Patients wh...">
  
  <meta property="og:url" content="https://airmedtrans.com/F6svLJO8B/">
  <meta property="og:site_name" content="王楠鑫|Curtis_一个医学译者的前后左右">

  <meta name="twitter:card" content="summary_large_image">
  <meta name="twitter:image:alt" content="医学翻译学习-alirocumab与急性冠脉综合征后的心血管结局">

  <meta name="gridea:post_id" content="AAdVfSCx7">

  <link rel="canonical" href="https://airmedtrans.com/F6svLJO8B">
  <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/highlight.js@10.0.3/styles/a11y-light.css">
  
  <link rel="stylesheet" href="//cdn.jsdelivr.net/npm/@gridea/theme@1.0.8/css/main.css">

</head>
<body>
  
    
  
  <div id="page">
    <div class="mb-16 sticky top-0 z-20 bg-white">
  <header class="py-4 flex items-baseline justify-between max-w-2xl mx-auto px-2">
    <h1 class="text-lg text-center font-medium px-4 md:px-0 flex items-center">
      <div class="site-logo-text font-normal">王</div>
      <a href="/">王楠鑫|Curtis_一个医学译者的前后左右</a>
    </h1>
    <div class="hidden sm:flex justify-center">
      
        
        <a
          href="https://airmedtrans.com/aboutme"
          class="mx-2 text-base border-b border-transparent"
          target="_blank"
        >关于我</a>
        
          <span class="text-gray-200">/</span>
        
      
        
        <a
          href="https://airmedtrans.com/contact me"
          class="mx-2 text-base border-b border-transparent"
          target="_blank"
        >联系我</a>
        
      
    </div>
    <div class="flex sm:hidden py-2 px-4 text-center cursor-pointer" @click="openMenu = true">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" height="24"><path fill="none" d="M0 0h24v24H0z"/><path d="M3 4h18v2H3V4zm0 7h18v2H3v-2zm0 7h18v2H3v-2z"/></svg>
    </div>
  </header>

  <div class="fixed top-0 right-0 bottom-0 left-0 bg-white hidden" :style="{
    display: openMenu ? 'block !important' : 'none',
  }" v-if="openMenu">
    <div class="py-4 px-2 flex justify-end" @click="openMenu = false">
      <div class="flex py-2 px-4 text-center cursor-pointer">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" height="24"><path fill="none" d="M0 0h24v24H0z"/><path d="M12 10.586l4.95-4.95 1.414 1.414-4.95 4.95 4.95 4.95-1.414 1.414-4.95-4.95-4.95 4.95-1.414-1.414 4.95-4.95-4.95-4.95L7.05 5.636z"/></svg>
      </div>
    </div>
    <div class="flex flex-col p-4">
      
        
        <a
          href="https://airmedtrans.com/aboutme"
          class="mx-2 my-4 text-base border-b border-transparent"
          target="_blank"
        >关于我</a>
      
        
        <a
          href="https://airmedtrans.com/contact me"
          class="mx-2 my-4 text-base border-b border-transparent"
          target="_blank"
        >联系我</a>
      
    </div>
  </div>
</div>
    <div class="border-b border-gray-200">
      <div class="max-w-2xl mx-auto px-6 md:px-2">
        <div class="my-24 text-center">
          <h1 class="text-2xl font-bold">医学翻译学习-alirocumab与急性冠脉综合征后的心血管结局</h1>
          <div class="post-title-bar mx-auto rounded mt-4"></div>
          <div class="text-gray-400 mt-4">2020.10.15</div>
          <div class="flex justify-center mt-4">
            
          </div>
        </div>
      </div>
    </div>
    <div id="sticky-bar" class="w-full sticky top-0 z-10 bg-white" style="height: 64px;"></div>
    <div class="p-4 md:p-16 bg-white">
      <div class="max-w-2xl mx-auto px-4 flex relative">
        <section class="post-content flex-1 default-post-content max-w-2xl">
          <div v-pre>
            <p>关于“alirocumab与急性冠脉综合征后的心血管结局”的翻译学习，学习内容记录于此。</p>
<p>旧文重发，时间为2019-03-15</p>
<!--more-->
<p>背景</p>
<p>BACKGROUND</p>
<blockquote>
<p>急性冠脉综合征患者发生复发性缺血性心血管事件的风险较高。</p>
<p>Patients <strong>who have had an acute coronary syndrome</strong> are <strong>at high risk for</strong> recurrent ischemic cardiovascular events.</p>
</blockquote>
<p>笔记：</p>
<p>A at high risk for B	A出现B的风险<strong>较</strong>高</p>
<p>recurrent ischemic cardiovascular event	复发性缺血性心血管事件</p>
<blockquote>
<p>我们试图确定在接受<strong>高强度他汀类药物治疗</strong>的患者中，alirocumab（前蛋白转化酶枯草溶菌素-9 [PCSK9]<strong>的人单克隆抗体</strong>）是否会改善<strong>急性冠脉综合征</strong>后的心血管结局。</p>
<p>We sought to determine whether alirocumab, <strong>a human monoclonal antibody to</strong> proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy.</p>
</blockquote>
<p>笔记：</p>
<p>a human monoclonal antibody to X	X的人单克隆抗体</p>
<p>acute coronary syndrome	急性冠脉综合征</p>
<p>high-intensity statin therapy	高强度他汀类药物治疗</p>
<p>句子逻辑：插入语；动名词做补充说明</p>
<p>方法</p>
<p>Methods</p>
<blockquote>
<p>我们在1～12个月前罹患急性冠脉综合征，低密度脂蛋白（LDL）胆固醇水平至少为70 mg/dL（1.8 mmol/L）、非高密度脂蛋白胆固醇水平至少为100 mg/dL（2.6 mmol/L）或载脂蛋白B水平至少为80 mg/dL，并且正在接受高强度剂量或最大耐受剂量他汀类药物治疗的18,924例患者中，开展了一项多中心、随机、双盲、安慰剂对照试验。</p>
<p>We conducted a multicenter, randomized, double-blind, placebo-controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low-density lipoprotein (LDL) cholesterol <strong>level of at least 70 mg per deciliter</strong> (1.8 mmol per liter), a non−high-density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high-intensity dose or at the maximum tolerated dose.</p>
</blockquote>
<p>笔记：</p>
<p>level of at least 70 mg per deciliter	至少为70 mg/dL</p>
<p>1.8 mmol per liter	1.8 mmol/L</p>
<p>maximum tolerated dose	MTD</p>
<p>句子逻辑：先说最重要的“开展了一项多中心、随机、双盲、安慰剂对照试验。”</p>
<p>中文表达：罹患</p>
<blockquote>
<p>患者被随机分组，接受75 mg剂量的alirocumab（9,462例患者）或匹配安慰剂（9,462例患者）每2周1次皮下给药。</p>
<p>Patients were randomly assigned to receive alirocumab <strong>subcutaneously</strong> at <strong>a</strong> dose of 75 mg (9462 patients) or <strong>matching</strong> placebo (9462 patients) every 2 weeks.</p>
</blockquote>
<p>笔记：</p>
<p>subcutaneously</p>
<p>at <strong>a</strong> dose of</p>
<p><strong>matching</strong> placebo</p>
<blockquote>
<p>在设盲的情况下调整alirocumab剂量，以25～50 mg/dL（0.6～1.3 mmol/L）的LDL胆固醇水平为目标。</p>
<p>The dose of alirocumab was <strong>adjusted under blinded conditions</strong> to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter).</p>
</blockquote>
<p>笔记：</p>
<p>adjusted under blinded conditions	在设盲的情况下调整</p>
<p>to target	target作动词</p>
<p>level of 25 to 50 mg	level of A to B (without &quot;from&quot;)</p>
<blockquote>
<p>主要终点是由冠心病死亡、非致死性心肌梗死、致死性或非致死性缺血性卒中或者需要住院的不稳定型心绞痛构成的复合终点。</p>
<p><strong>The primary end point was a composite of</strong> death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization.</p>
</blockquote>
<p>笔记：</p>
<p>death from coronary heart disease	冠心病死亡</p>
<p>nonfatal myocardial infarction	非致死性心肌梗死</p>
<p>fatal or nonfatal ischemic stroke	致死性或非致死性缺血性卒中</p>
<p>unstable angina requiring hospitalization	需要住院的不稳定型心绞痛</p>
<p>The primary end point was a <strong>composite</strong> of ···	主要终点是由······构成的复合终点</p>
<p>结果</p>
<p>RESULTS</p>
<blockquote>
<p>中位随访持续时间为2.8年。</p>
<p>The median duration of follow-up was 2.8 years.</p>
</blockquote>
<p>笔记：</p>
<p>随访没有再加一个visit</p>
<blockquote>
<p>alirocumab组903例患者（9.5%）和安慰剂组1,052例患者（11.1%）发生了<strong>复合主要终点事件</strong>（风险比，0.85；95%置信区间[<em>CI</em>]，0.78～0.93；<em>P</em>＜0.001）。</p>
<p>A composite primary end-point event <strong>occurred in</strong> 903 patients (9.5%) in the alirocumab group and in 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% confidence interval [CI], 0.78 to 0.93; P&lt;0.001).</p>
</blockquote>
<p>笔记：</p>
<p>composite primary end-point event	复合主要终点事件</p>
<blockquote>
<p>共有alirocumab组334例患者（3.5%）和安慰剂组392例患者（4.1%）死亡（风险比，0.85；95% <em>CI</em>，0.73～0.98）。</p>
<p>A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group died (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).</p>
</blockquote>
<blockquote>
<p>在基线LDL胆固醇水平≥100 mg/dL的患者中，alirocumab在复合主要终点方面的绝对获益大于基线水平较低的患者。</p>
<p>The <strong>absolute benefit</strong> of alirocumab <strong>with respect to</strong> the composite primary end point was greater among patients who had a baseline LDL cholesterol <strong>level of 100 mg or more per deciliter</strong> than among patients who had a lower baseline level.</p>
</blockquote>
<p>笔记：</p>
<p>absolute benefit	绝对获益</p>
<p>with respect to	在······方面</p>
<p>除了局部注射部位反应（alirocumab组3.8% *vs.*安慰剂组2.1%）之外，两组的不良事件发生率相似。</p>
<p>The incidence of adverse events was similar in the two groups, with the exception of local injection-site reactions (3.8% in the alirocumab group vs. 2.1% in the placebo group).</p>
<p>结论</p>
<p>CONCLUSIONS</p>
<blockquote>
<p>在既往患急性冠脉综合征并且正在接受高强度他汀类药物治疗的患者中，接受alirocumab治疗患者的复发性缺血性心血管事件风险低于接受安慰剂治疗的患者（由赛诺菲和再生元制药[Regeneron Pharmaceuticals]资助；ODYSSEY OUTCOMES在ClinicalTrials.gov注册号为NCT01663402）。</p>
<p>Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT01663402">NCT01663402</a>.)</p>
</blockquote>
<p>笔记：</p>
<p>时态很有意思。</p>
<blockquote>
<p>虽然目前有循证治疗方法，但急性冠脉综合征患者发生复发性缺血性心血管事件的风险仍然较高<a href="http:/#1,2">1,2</a>。</p>
<p>Despite <strong>the availability of</strong> current evidence-based treatments, patients who have had an acute coronary syndrome remain at high risk for recurrent ischemic cardiovascular events.1,2</p>
</blockquote>
<p>笔记：</p>
<p>the availability of</p>
<blockquote>
<p>这种残留风险部分是由于低密度脂蛋白（LDL）胆固醇和其他致动脉粥样硬化脂蛋白水平升高引起。</p>
<p>This residual risk <strong>is attributable</strong> in part to elevated levels of low-density lipoprotein (LDL) cholesterol and other atherogenic lipoproteins.</p>
</blockquote>
<p>笔记：</p>
<p>be attributable to 是由于</p>
<blockquote>
<p>之前的临床试验已经表明，接受他汀类药物治疗以降低LDL胆固醇水平的患者，其风险低于接受安慰剂治疗的患者<a href="http:/#3">3</a>，接受高强度他汀类药物治疗的患者，其风险低于接受中等强度他汀类药物治疗的患者<a href="http:/#4">4</a>，并且接受他汀类药物+依折麦布治疗的患者，其风险低于接受他汀类药物单独治疗的患者<a href="http:/#5">5</a>。</p>
<p>Previous clinical trials have shown that the risk is lower among patients who receive statin therapy to lower the LDL cholesterol level than among those who receive placebo,3 among patients who receive high-intensity statins than among those who receive moderateintensity statins,4 and among patients who receive ezetimibe added to statin therapy than among those who receive a statin alone.5</p>
</blockquote>
<p>笔记：</p>
<p>比较级经典用法</p>
<blockquote>
<p>PCSK9能够促进LDL受体降解，从而减少循环系统内LDL的清除<a href="http:/#6">6</a>。</p>
<p>Proprotein convertase subtilisin–kexin type 9 (PCSK9) promotes degradation of LDL receptors, thereby diminishing the clearance of LDL from the circulation.6</p>
</blockquote>
<p>笔记：</p>
<p>动名词经典用法</p>
<blockquote>
<p>研究已经表明，导致PCSK9功能获得或丧失的突变会分别导致较高或较低的LDL胆固醇水平，这又与相应较高<a href="http:/#7">7</a>或较低<a href="http:/#6">6</a>的新发冠心病风险相关。</p>
<p>Studies have shown that mutations <strong>conveying</strong> gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher7 or lower6 risk of incident coronary heart disease.</p>
</blockquote>
<blockquote>
<p>这些发现促使我们开发出PCSK9的单克隆抗体，当单独给药或与他汀类药物联合用药时，PCSK9单克隆抗体能够显著降低LDL胆固醇水平<a href="http:/#8-12">8-12</a>。</p>
<p>These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol **when administered alone or with a statin.**8-12</p>
</blockquote>
<p>笔记：</p>
<p>不重要的部分，在英文中的处理值得注意</p>
<p>“PCSK9单克隆抗体”的处理值得学习</p>
<blockquote>
<p>在此类药物中，据报告有两种能够降低患稳定型动脉粥样硬化疾病或具有高心血管风险，并且虽然接受他汀类药物治疗，但致动脉粥样硬化脂蛋白水平仍然升高的患者的缺血性心血管事件风险<a href="http:/#11,13">11,13</a>，其中一种药物仅在基线LDL胆固醇水平至少为100 mg/dL（2.6 mmol/L）的患者中显示出获益<a href="http:/#12">12</a>。</p>
<p>Two of these agents were reported to reduce the risk of ischemic cardiovascular events in patients who had stable atherosclerotic disease or high cardiovascular risk and an elevated level of atherogenic lipoproteins despite statin treatment,11,13 <strong>with</strong> one agent showing benefit only among patients who had a baseline<br>
LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter).12</p>
</blockquote>
<p>笔记：</p>
<p>With 结构</p>
<blockquote>
<p>迄今，PCSK9抗体在急性冠脉综合征后降低心血管风险的潜在作用仍然未确定。</p>
<p>To date, the potential for a PCSK9 antibody to reduce cardiovascular risk after an acute coronary<br>
syndrome remains undetermined.</p>
</blockquote>
<blockquote>
<p>在ODYSSEY OUTCOMES试验中，我们检验了以下假设，在之前1～12个月内罹患急性冠脉综合征，并且虽然接受高强度剂量或最大耐受剂量的他汀类药物治疗，但致动脉粥样硬化脂蛋白水平仍超过规定阈值的患者中，alirocumab（PCSK9的一种完全人单克隆抗体<a href="http:/#13-15">13-15</a>）治疗与安慰剂相比能够获得较低的复发性缺血性心血管事件风险。</p>
<p>In the ODYSSEY OUTCOMES trial, we tested the hypothesis that treatment with alirocumab, a fully human monoclonal antibody to PCSK9,13-15 would result in a lower risk of recurrent ischemic cardiovascular events than placebo among patients who had an acute coronary syndrome within the <strong>preceding</strong> 1 to 12 months and who have levels of atherogenic lipoproteins that exceed specified thresholds despite statin therapy at a high-intensity dose or at the maximum tolerated dose.</p>
</blockquote>
<p>笔记：</p>
<p>preceding</p>
<p>（英文为NEJM原文，中文为NEJM医学前沿官方译文。）</p>
<hr>
<p>作者简介：</p>
<p>四川外国语大学成都学院翻译系英语（翻译方向）专业</p>
<p>重庆医科大学外国语学院英语笔译专业</p>
<p><strong>英语专业八级</strong></p>
<p><strong>人事部三级、二级英语笔译资格证书持证</strong></p>
<p><strong>人事部三级英语口译资格证书持证</strong></p>
<p>文思海辉技术有限公司    QQ音乐歌词翻译（全职，2014年年度优秀新人）</p>
<p>重庆润泽医药有限公司    医学翻译实习生（翻译、数据整理）</p>
<p>成都创思立信信息技术有限公司 医学翻译实习生（翻译、校对）；<strong>医学翻译、校对、导师、项目经理</strong></p>
<p>曾多次为凤凰科技，解放军某高校，成都某化妆品公司提供翻译服务</p>
<p>工作邮箱：wnxcn@foxmail.com</p>

          </div>
          <div class="py-4 text-gray-600 flex items-center justify-between">
            <div class="">
              <div class="text-sm text-gray-300">最后更新于: </div>
              <div class="text-base font-medium">2020.10.15</div>
            </div>
            <!-- <div class="flex items-center text-sm text-gray-600">
              <i class="ri-eye-line"></i> <span class="ml-2">{{ views }}</span>
            </div> -->
          </div>
          <div>
            <div id="disqus_thread"></div>
          </div>
        </section>
        
      </div>
    </div>
    <div class="py-8 text-gray-300 text-center border-t border-gray-200">
  Powered by Gridea
</div>
  </div>

  <script src="//cdn.jsdelivr.net/npm/vue@2.6.11"></script>
  
  <script src="//cdn.jsdelivr.net/npm/@gridea/theme@1.0.8/js/main.js"></script>

  <script src="//cdn.jsdelivr.net/gh/highlightjs/cdn-release@10.0.0/build/highlight.min.js"></script>
  <script>hljs.initHighlightingOnLoad();</script>
  
    <script>

/**
*  RECOMMENDED CONFIGURATION VARIABLES: EDIT AND UNCOMMENT THE SECTION BELOW TO INSERT DYNAMIC VALUES FROM YOUR PLATFORM OR CMS.
*  LEARN WHY DEFINING THESE VARIABLES IS IMPORTANT: https://disqus.com/admin/universalcode/#configuration-variables*/
/*
var disqus_config = function () {
this.page.url = PAGE_URL;  // Replace PAGE_URL with your page's canonical URL variable
this.page.identifier = PAGE_IDENTIFIER; // Replace PAGE_IDENTIFIER with your page's unique identifier variable
};
*/
(function() { // DON'T EDIT BELOW THIS LINE
var d = document, s = d.createElement('script');
s.src = 'https://airmedtrans-com.disqus.com/embed.js';
s.setAttribute('data-timestamp', +new Date());
(d.head || d.body).appendChild(s);
})();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
                            
  
  
    
  
</body>
</html>